Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
Identifieur interne : 002745 ( PubMed/Curation ); précédent : 002744; suivant : 002746Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
Auteurs : Georg Auzinger [Royaume-Uni] ; E Geoffrey Playford [Australie] ; Christopher N. Graham [États-Unis] ; Hediyyih N. Knox [États-Unis] ; David Weinstein [France] ; Michal Kantecki [France] ; Haran Schlamm [États-Unis] ; Claudie Charbonneau [France]Source :
- BMC infectious diseases [ 1471-2334 ] ; 2015.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice, Antifongiques (effets indésirables), Antifongiques (usage thérapeutique), Antifongiques (économie), Candidose invasive (mortalité), Candidose invasive (traitement médicamenteux), Candidose invasive (économie), Candidémie (traitement médicamenteux), Coûts des médicaments, Durée du séjour (économie), Fluconazole (usage thérapeutique), Fluconazole (économie), Humains, Lipopeptides (usage thérapeutique), Lipopeptides (économie), Modèles économiques, Royaume-Uni, Résultat thérapeutique, Unités de soins intensifs (économie), Échinocandines (usage thérapeutique), Échinocandines (économie).
- MESH :
- effets indésirables : Antifongiques.
- mortalité : Candidose invasive.
- traitement médicamenteux : Candidose invasive, Candidémie.
- usage thérapeutique : Antifongiques, Fluconazole, Lipopeptides, Échinocandines.
- économie : Antifongiques, Candidose invasive, Durée du séjour, Fluconazole, Lipopeptides, Unités de soins intensifs, Échinocandines.
- Analyse coût-bénéfice, Coûts des médicaments, Humains, Modèles économiques, Royaume-Uni, Résultat thérapeutique.
English descriptors
- KwdEn :
- Antifungal Agents (adverse effects), Antifungal Agents (economics), Antifungal Agents (therapeutic use), Candidemia (drug therapy), Candidiasis, Invasive (drug therapy), Candidiasis, Invasive (economics), Candidiasis, Invasive (mortality), Cost-Benefit Analysis, Drug Costs, Echinocandins (economics), Echinocandins (therapeutic use), Fluconazole (economics), Fluconazole (therapeutic use), Humans, Intensive Care Units (economics), Length of Stay (economics), Lipopeptides (economics), Lipopeptides (therapeutic use), Models, Economic, Treatment Outcome, United Kingdom.
- MESH :
- chemical , adverse effects : Antifungal Agents.
- chemical , economics : Antifungal Agents, Echinocandins, Fluconazole, Lipopeptides.
- chemical , therapeutic use : Antifungal Agents, Echinocandins, Fluconazole, Lipopeptides.
- drug therapy : Candidemia, Candidiasis, Invasive.
- economics : Candidiasis, Invasive, Intensive Care Units, Length of Stay.
- mortality : Candidiasis, Invasive.
- Cost-Benefit Analysis, Drug Costs, Humans, Models, Economic, Treatment Outcome, United Kingdom.
Abstract
Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines.
DOI: 10.1186/s12879-015-1143-1
PubMed: 26503366
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002814
Links to Exploration step
pubmed:26503366Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.</title><author><name sortKey="Auzinger, Georg" sort="Auzinger, Georg" uniqKey="Auzinger G" first="Georg" last="Auzinger">Georg Auzinger</name><affiliation wicri:level="1"><nlm:affiliation>King's College Hospital, London, UK. georg.auzinger@nhs.net.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Playford, E Geoffrey" sort="Playford, E Geoffrey" uniqKey="Playford E" first="E Geoffrey" last="Playford">E Geoffrey Playford</name><affiliation wicri:level="1"><nlm:affiliation>Princess Alexandra Hospital, Brisbane, Australia. geoffrey_playford@health.qld.gov.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Brisbane</wicri:regionArea></affiliation></author><author><name sortKey="Graham, Christopher N" sort="Graham, Christopher N" uniqKey="Graham C" first="Christopher N" last="Graham">Christopher N. Graham</name><affiliation wicri:level="1"><nlm:affiliation>RTI Health Solutions, Research Triangle Park, Durham, NC, USA. cgraham@rti.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI Health Solutions, Research Triangle Park, Durham, NC</wicri:regionArea></affiliation></author><author><name sortKey="Knox, Hediyyih N" sort="Knox, Hediyyih N" uniqKey="Knox H" first="Hediyyih N" last="Knox">Hediyyih N. Knox</name><affiliation wicri:level="1"><nlm:affiliation>RTI Health Solutions, Research Triangle Park, Durham, NC, USA. hknox@rti.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI Health Solutions, Research Triangle Park, Durham, NC</wicri:regionArea></affiliation></author><author><name sortKey="Weinstein, David" sort="Weinstein, David" uniqKey="Weinstein D" first="David" last="Weinstein">David Weinstein</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer International Operations, Paris, France. douvedel@yahoo.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Kantecki, Michal" sort="Kantecki, Michal" uniqKey="Kantecki M" first="Michal" last="Kantecki">Michal Kantecki</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer International Operations, Paris, France. Michal.Kantecki@Pfizer.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Schlamm, Haran" sort="Schlamm, Haran" uniqKey="Schlamm H" first="Haran" last="Schlamm">Haran Schlamm</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Inc, New York, NY, USA. HTSchlamm@att.net.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Inc, New York, NY</wicri:regionArea></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer International Operations, Paris, France. claudie.charbonneau@pfizer.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26503366</idno><idno type="pmid">26503366</idno><idno type="doi">10.1186/s12879-015-1143-1</idno><idno type="wicri:Area/PubMed/Corpus">002814</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002814</idno><idno type="wicri:Area/PubMed/Curation">002745</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002745</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.</title><author><name sortKey="Auzinger, Georg" sort="Auzinger, Georg" uniqKey="Auzinger G" first="Georg" last="Auzinger">Georg Auzinger</name><affiliation wicri:level="1"><nlm:affiliation>King's College Hospital, London, UK. georg.auzinger@nhs.net.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Playford, E Geoffrey" sort="Playford, E Geoffrey" uniqKey="Playford E" first="E Geoffrey" last="Playford">E Geoffrey Playford</name><affiliation wicri:level="1"><nlm:affiliation>Princess Alexandra Hospital, Brisbane, Australia. geoffrey_playford@health.qld.gov.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Brisbane</wicri:regionArea></affiliation></author><author><name sortKey="Graham, Christopher N" sort="Graham, Christopher N" uniqKey="Graham C" first="Christopher N" last="Graham">Christopher N. Graham</name><affiliation wicri:level="1"><nlm:affiliation>RTI Health Solutions, Research Triangle Park, Durham, NC, USA. cgraham@rti.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI Health Solutions, Research Triangle Park, Durham, NC</wicri:regionArea></affiliation></author><author><name sortKey="Knox, Hediyyih N" sort="Knox, Hediyyih N" uniqKey="Knox H" first="Hediyyih N" last="Knox">Hediyyih N. Knox</name><affiliation wicri:level="1"><nlm:affiliation>RTI Health Solutions, Research Triangle Park, Durham, NC, USA. hknox@rti.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI Health Solutions, Research Triangle Park, Durham, NC</wicri:regionArea></affiliation></author><author><name sortKey="Weinstein, David" sort="Weinstein, David" uniqKey="Weinstein D" first="David" last="Weinstein">David Weinstein</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer International Operations, Paris, France. douvedel@yahoo.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Kantecki, Michal" sort="Kantecki, Michal" uniqKey="Kantecki M" first="Michal" last="Kantecki">Michal Kantecki</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer International Operations, Paris, France. Michal.Kantecki@Pfizer.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Schlamm, Haran" sort="Schlamm, Haran" uniqKey="Schlamm H" first="Haran" last="Schlamm">Haran Schlamm</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Inc, New York, NY, USA. HTSchlamm@att.net.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Inc, New York, NY</wicri:regionArea></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer International Operations, Paris, France. claudie.charbonneau@pfizer.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea></affiliation></author></analytic><series><title level="j">BMC infectious diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antifungal Agents (adverse effects)</term><term>Antifungal Agents (economics)</term><term>Antifungal Agents (therapeutic use)</term><term>Candidemia (drug therapy)</term><term>Candidiasis, Invasive (drug therapy)</term><term>Candidiasis, Invasive (economics)</term><term>Candidiasis, Invasive (mortality)</term><term>Cost-Benefit Analysis</term><term>Drug Costs</term><term>Echinocandins (economics)</term><term>Echinocandins (therapeutic use)</term><term>Fluconazole (economics)</term><term>Fluconazole (therapeutic use)</term><term>Humans</term><term>Intensive Care Units (economics)</term><term>Length of Stay (economics)</term><term>Lipopeptides (economics)</term><term>Lipopeptides (therapeutic use)</term><term>Models, Economic</term><term>Treatment Outcome</term><term>United Kingdom</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Antifongiques (effets indésirables)</term><term>Antifongiques (usage thérapeutique)</term><term>Antifongiques (économie)</term><term>Candidose invasive (mortalité)</term><term>Candidose invasive (traitement médicamenteux)</term><term>Candidose invasive (économie)</term><term>Candidémie (traitement médicamenteux)</term><term>Coûts des médicaments</term><term>Durée du séjour (économie)</term><term>Fluconazole (usage thérapeutique)</term><term>Fluconazole (économie)</term><term>Humains</term><term>Lipopeptides (usage thérapeutique)</term><term>Lipopeptides (économie)</term><term>Modèles économiques</term><term>Royaume-Uni</term><term>Résultat thérapeutique</term><term>Unités de soins intensifs (économie)</term><term>Échinocandines (usage thérapeutique)</term><term>Échinocandines (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antifungal Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antifungal Agents</term><term>Echinocandins</term><term>Fluconazole</term><term>Lipopeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antifungal Agents</term><term>Echinocandins</term><term>Fluconazole</term><term>Lipopeptides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Candidemia</term><term>Candidiasis, Invasive</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Candidiasis, Invasive</term><term>Intensive Care Units</term><term>Length of Stay</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antifongiques</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Candidiasis, Invasive</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Candidose invasive</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Candidose invasive</term><term>Candidémie</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antifongiques</term><term>Fluconazole</term><term>Lipopeptides</term><term>Échinocandines</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antifongiques</term><term>Candidose invasive</term><term>Durée du séjour</term><term>Fluconazole</term><term>Lipopeptides</term><term>Unités de soins intensifs</term><term>Échinocandines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Drug Costs</term><term>Humans</term><term>Models, Economic</term><term>Treatment Outcome</term><term>United Kingdom</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Coûts des médicaments</term><term>Humains</term><term>Modèles économiques</term><term>Royaume-Uni</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26503366</PMID><DateCreated><Year>2015</Year><Month>10</Month><Day>27</Day></DateCreated><DateCompleted><Year>2016</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2015</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.</ArticleTitle><Pagination><MedlinePgn>463</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-015-1143-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Costs and treatment outcomes with the echinocandin anidulafungin were compared with those for caspofungin, micafungin and fluconazole. The model included non-neutropenic patients aged ≥16 years with confirmed C/IC who were receiving intravenous first-line treatment. Patients were categorised as either a clinical success or failure (patients with persistent/breakthrough infection); successfully treated patients switched to oral therapy, while patients categorised as clinical failures switched to a different antifungal class. Other inputs were all-cause mortality at 6 weeks, costs of treatment-related adverse events and other medical resource utilisation costs. Resource use was derived from the published literature and from discussion with clinical experts. Drug-acquisition/administration costs were taken from standard United Kingdom costing sources.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The model indicated that first-line anidulafungin could be considered cost-effective versus fluconazole (incremental cost-effectiveness ratio £813 per life-year gained) for the treatment of C/IC. Anidulafungin was cost-saving versus caspofungin and micafungin due to lower total costs and a higher rate of survival combined with a higher probability of clinical success.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">European Society for Clinical Microbiology and Infectious Diseases guidelines recommend echinocandins for the first-line treatment of C/IC; our model indicated that anidulafungin marries clinical effectiveness and cost-effectiveness.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">From the United Kingdom perspective, anidulafungin was cost-effective compared with fluconazole for the treatment of C/IC and was cost-saving versus the other echinocandins.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Auzinger</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>King's College Hospital, London, UK. georg.auzinger@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Playford</LastName><ForeName>E Geoffrey</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Brisbane, Australia. geoffrey_playford@health.qld.gov.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Christopher N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>RTI Health Solutions, Research Triangle Park, Durham, NC, USA. cgraham@rti.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knox</LastName><ForeName>Hediyyih N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>RTI Health Solutions, Research Triangle Park, Durham, NC, USA. hknox@rti.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pfizer International Operations, Paris, France. douvedel@yahoo.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantecki</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pfizer International Operations, Paris, France. Michal.Kantecki@Pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlamm</LastName><ForeName>Haran</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, NY, USA. HTSchlamm@att.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charbonneau</LastName><ForeName>Claudie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pfizer International Operations, Paris, France. claudie.charbonneau@pfizer.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054714">Echinocandins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055666">Lipopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>8VZV102JFY</RegistryNumber><NameOfSubstance UI="D015725">Fluconazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>9HLM53094I</RegistryNumber><NameOfSubstance UI="C102786">anidulafungin</NameOfSubstance></Chemical><Chemical><RegistryNumber>F0XDI6ZL63</RegistryNumber><NameOfSubstance UI="C105417">caspofungin</NameOfSubstance></Chemical><Chemical><RegistryNumber>R10H71BSWG</RegistryNumber><NameOfSubstance UI="C121905">micafungin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Diagn Microbiol Infect Dis. 1999 Aug;34(4):281-6</RefSource><PMID Version="1">10459478</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2006;6:21</RefSource><PMID Version="1">16472387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Rev. 2007 Jan;20(1):133-63</RefSource><PMID Version="1">17223626</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Jun 14;356(24):2472-82</RefSource><PMID Version="1">17568028</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i3-6</RefSource><PMID Version="1">18063601</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Infect. 2008 May;14(5):487-94</RefSource><PMID Version="1">18294241</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Mar 1;48(5):503-35</RefSource><PMID Version="1">19191635</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Med Res Opin. 2009 Aug;25(8):2049-59</RefSource><PMID Version="1">19575628</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Clin Microbiol Antimicrob. 2009;8:23</RefSource><PMID Version="1">19558681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Pharmacother. 2009 Oct;43(10):1647-57</RefSource><PMID Version="1">19724014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Pharmacother. 2010 Apr;11(6):877-87</RefSource><PMID Version="1">20201729</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Crit Care Med. 2011 Apr;39(4):665-70</RefSource><PMID Version="1">21169817</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2011 Aug;66(8):1906-15</RefSource><PMID Version="1">21628305</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Antimicrob Agents. 2011 Nov;38(5):417-20</RefSource><PMID Version="1">21885259</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Crit Care. 2011;15(5):R253</RefSource><PMID Version="1">22026929</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37</RefSource><PMID Version="1">23137135</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Crit Care. 2012;16(3):R105</RefSource><PMID Version="1">22698004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2000 Jun;18(12):2476-83</RefSource><PMID Version="1">10856108</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Surg. 2000 Feb;135(2):160-5</RefSource><PMID Version="1">10668874</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Pharmacol Toxicol. 2014;15:52</RefSource><PMID Version="1">25253630</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2002 Sep 1;35(5):627-30</RefSource><PMID Version="1">12173140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Manag Care Pharm. 2003 Jan-Feb;9(1):53-61</RefSource><PMID Version="1">14613362</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):317-22</RefSource><PMID Version="1">15029512</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 1997 Apr 2;277(13):1058-63</RefSource><PMID Version="1">9091694</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058387" MajorTopicYN="N">Candidemia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058365" MajorTopicYN="N">Candidiasis, Invasive</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016527" MajorTopicYN="N">Drug Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054714" MajorTopicYN="N">Echinocandins</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015725" MajorTopicYN="N">Fluconazole</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055666" MajorTopicYN="N">Lipopeptides</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4623895</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>02</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26503366</ArticleId><ArticleId IdType="doi">10.1186/s12879-015-1143-1</ArticleId><ArticleId IdType="pii">10.1186/s12879-015-1143-1</ArticleId><ArticleId IdType="pmc">PMC4623895</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002745 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002745 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26503366
|texte= Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26503366" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |